Signaturefd LLC Sells 1,459 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Signaturefd LLC has reduced its stake in Thermo Fisher Scientific Inc. by 17.9%, selling 1,459 shares and now holding a total of 6,708 shares valued at approximately $2.72 million.
• In the latest analyst updates, Evercore ISI and HSBC Global Research both adjusted their ratings, with the average price target set at $588.35, indicating a consensus of "Moderate Buy."
• Thermo Fisher Scientific reported $5.36 EPS for its most recent quarter, exceeding expectations, with revenue of $10.86 billion. The company also announced a quarterly dividend of $0.43 per share.

Signaturefd LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 17.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,708 shares of the medical research company's stock after selling 1,459 shares during the period. Signaturefd LLC's holdings in Thermo Fisher Scientific were worth $2,720,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. CBIZ Investment Advisory Services LLC grew its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares in the last quarter. Anderson Financial Strategies LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter worth about $30,000. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter worth about $31,000. IMA Advisory Services Inc. bought a new position in shares of Thermo Fisher Scientific in the first quarter worth about $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in Thermo Fisher Scientific in the 1st quarter valued at approximately $37,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TMO. Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research report on Friday, July 11th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating for the company. Finally, Raymond James Financial reissued an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $464.18 on Friday. The firm has a market cap of $175.28 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The business has a 50 day moving average price of $476.70 and a 200-day moving average price of $447.57.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm's revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.